Valuation: BioNTech SE

Market Cap 21.55B 24.66B 19.81B 18.46B 35.02B 2,348B 35.55B 238B 92.45B 1,154B 92.55B 90.56B 3,977B P/E 2026 *
-19.4x
P/E 2027 * -19.1x
Enterprise Value 10.7B 12.24B 9.84B 9.17B 17.39B 1,166B 17.65B 118B 45.9B 573B 45.95B 44.97B 1,974B EV / Sales 2026 *
4.94x
EV / Sales 2027 * 5.5x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-1.23%
Current month-5.31%
Current year-5.31%
3 years 84.05
Extreme 84.05
115.95
5 years 84.05
Extreme 84.05
396.5
10 years 11.5
Extreme 11.5
396.5
Manager TitleAgeSince
Chief Executive Officer 60 02/06/2008
Chief Tech/Sci/R&D Officer 59 01/01/2018
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-1.23%+5.52% - - 24.67B
+0.68%+5.92%+80.45%+137.78% 59.1B
+2.32%+5.03%+75.51%+94.88% 55.19B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+45.58%-1.42% 19.69B
-0.29%+9.78%+44.62%-27.94% 17.56B
0.00%+20.78%+178.93%+360.74% 16.22B
+3.50%+1.97%+21.02%+191.95% 14.04B
+6.72%+19.38%+42.82% - 14.84B
+2.67%+3.01%+76.70%+133.90% 12.18B
Average +2.34%+7.95%+64.42%+165.97% 25.89B
Weighted average by Cap. +1.99%+6.08%+67.43%+154.14%

Financials

2026 *2027 *
Net sales 2.17B 2.48B 1.99B 1.86B 3.52B 236B 3.57B 23.9B 9.29B 116B 9.3B 9.1B 400B 2.23B 2.55B 2.05B 1.91B 3.62B 243B 3.68B 24.61B 9.57B 119B 9.58B 9.37B 412B
Net income -1.05B -1.2B -966M -900M -1.71B -114B -1.73B -11.59B -4.51B -56.26B -4.51B -4.42B -194B -1.17B -1.33B -1.07B -998M -1.89B -127B -1.92B -12.86B -5B -62.39B -5B -4.9B -215B
Net Debt -10.85B -12.41B -9.97B -9.3B -17.63B -1,182B -17.9B -120B -46.54B -581B -46.6B -45.6B -2,002B -9.28B -10.62B -8.53B -7.95B -15.08B -1,011B -15.31B -102B -39.8B -497B -39.85B -38.99B -1,712B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
03/07/26 €84.05 -1.23% 6,674
02/07/26 €85.10 +3.21% 5,537
01/07/26 €82.45 +1.23% 1,883
30/06/26 €81.45 -1.09% 2,787
29/06/26 €82.35 +3.39% 4,516
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
85.23EUR
Average target price
106.75EUR
Spread / Average Target
+25.25%

Quarterly revenue - Rate of surprise